Jon has been reporting on stock markets for over twenty-five years for audio text companies (remember them?!), newswires, and websites. He helped set up MarketEye News for ICV/Topic in the 1990’s before moving on to become a Markets reporter at AFX News. After over 10 years, which saw him rise to the dizzy heights of Markets Editor at AFX, the firm’s acquisition by Thomson Corp and subsequent takeover of Reuters, he moved on in 2012. Prior to Proactive Investors, he was News Editor for thisismoney.co.uk, the Mail Online’s financial website.
In a pre-close trading update, the specialty pharmaceutical company said it performed well in the first half with sales for the period up 8% at £50.3mln, against £46.4mln at the same stage in 2016
The NYSE-listed firm said it will used the proceeds of its recent sale of Dendreon Pharmaceuticals LLC to pay off the loans.
The global bank has raised its stance to ‘hold’ from ‘reduce’ after making minor changes to its earnings per share estimates, while leaving its target price unchanged at 4,450p.
The firm said average selling prices exceeded £280,000 per unit during the period, up from £265,000 in 2016, and the group's total forward order book has increased by £241m since 1 March
The consortium includes AB Segulah - a significant shareholder of Advanced Oncotherapy - and a group of Swedish investors, including AFMS Radgivning Och Invest AB, Peter Gyllenhammar AB, Mijesi AB and Emendum AB
Silence noted a press release from Alnylam Pharmaceutical Inc on July 7 which stated that "Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors"
The claim asks the court to determine whether Silence is entitled to supplementary protection certificates on several late stage Alnylam Pharmacueticals Inc products, developed with partner, The Medicines Co
The broker adjusted its target for Motif Bio’s shares down to 100p, from 125p previously, with the shares currently trading at 31.25p in late morning trade, down 0.5p on the day